These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 21469973)

  • 1. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
    Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
    Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
    Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
    Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
    Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
    Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
    White WB; Pitt B; Preston RA; Hanes V
    Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
    Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
    Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
    Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA
    J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
    Genazzani AR; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Climacteric; 2013 Aug; 16(4):490-8. PubMed ID: 23531117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drospirenone and estradiol: a new option for the postmenopausal woman.
    Archer DF
    Climacteric; 2007 Feb; 10 Suppl 1():3-10. PubMed ID: 17364592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
    Mizunuma H
    Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
    Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
    Gynecol Endocrinol; 2001 Oct; 15(5):349-58. PubMed ID: 11727357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
    Palacios S; Foidart JM; Genazzani AR
    Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
    Junge W; El-Samalouti V; Gerlinger C; Schaefers M
    Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial.
    Honjo H; Taketani Y
    Climacteric; 2009 Aug; 12(4):319-28. PubMed ID: 19330598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
    Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
    Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
    Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
    Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
    Archer DF;
    Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
    Simon JA;
    Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.